VENANTIUS LTD has a total of 38 patent applications. Its first patent ever was published in 1996. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets organic fine chemistry and pharmaceuticals are VENANTIUS LIMITED, SCHWARZ PHARMA LTD and TOA EIYO KAGAKU KOGYO KK.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 7 | |
#2 | United States | 6 | |
#3 | WIPO (World Intellectual Property Organization) | 4 | |
#4 | Australia | 3 | |
#5 | Canada | 3 | |
#6 | Ireland | 3 | |
#7 | South Africa | 3 | |
#8 | Israel | 2 | |
#9 | Taiwan | 2 | |
#10 | Brazil | 1 | |
#11 | China | 1 | |
#12 | Hong Kong | 1 | |
#13 | New Zealand | 1 | |
#14 | Russian Federation | 1 |
# | Industry | |
---|---|---|
#1 | Organic fine chemistry | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Acyclic or carbocyclic compounds | |
#3 | Organic chemistry methods | |
#4 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Sheridan Helen | 34 |
#2 | Frankish Neil | 34 |
#3 | Byrne William | 16 |
#4 | Walsh John | 14 |
#5 | Farrell Ronan | 5 |
#6 | Jordan Michael | 3 |
#7 | Walsh John Jr | 2 |
#8 | Neil Frankish | 1 |
#9 | Sheridan Helen H | 1 |
#10 | Helen Sheridan | 1 |
Publication | Filing date | Title |
---|---|---|
EP2864279A1 | Compounds for use in the treatment of autoimmune inflammatory disease | |
EP2855416A1 | Indane dimers for use in the treatment of autoimmune inflammatory disease | |
EP2734496A1 | Indene derivatives for use in the treatment of inflammatory bowel disease | |
EP2734497A1 | Indane dimers for use in the treatment of autoimmune inflammatory disease | |
IE980421A1 | 3-Aminoindanones of the formula 1 are described for pharmaceutical use, especially as antiinflammatory agents and/or mast cell stabilising agents. | |
IE980422A1 | Compounds | |
ZA9610304B | Indane dimer compounds, processes for their manufacture and their pharmaceutical use. |